Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06048666
Other study ID # PRP in poor ovarian reserve
Secondary ID
Status Not yet recruiting
Phase Phase 3
First received
Last updated
Start date October 30, 2023
Est. completion date September 30, 2024

Study information

Verified date September 2023
Source Beni-Suef University
Contact Beni-suef University
Phone 082 2318605
Email fom@med.bsu.edu.eg
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this study is to evaluate the efficacy of intra ovarian injection of autologous platelet rich plasma on ovarian reserve parameters and ICSI outcomes in poor ovarian reserve.


Description:

fifty_six infertile women suffering from poor ovarian reserve &following up at IVF Unit of Beni_suef University hospital. , and they fulfilled inclusion and exclusion criteria. they will be classlfied into two groups: Group A (study group) (involve 28 patient ):will be injected intra ovarian by platelet rich plasma Group B (control group) (involve 28 patient): will not be injected intra ovarian by platelet rich Plasma The researcher will introduce himself to all participants included in this study and requested that they participate after explaining the purpose of the study. All participants will be given detailed information about the study's goal and predicted advantages. All participants will give their informed verbal agreement, and the data will be kept confidential. All patients will be subjected to: Complete history was taken with special emphasis on: Personal ,past,family&surgical history. Menstrual historyObstetric history Clinical examination: Physical examination included General examination: Weight, Height, BMI, Abdominal examination , Local (Pelvic) examination Ultrasound examination: The women will be in lithotomy position with an empty bladder. On day 2 of the menstrual cycle or withdrawal bleed, a sterile vaginal speculum has been introduced, and a TV ultrasonography probe (7.0-MH endo-vaginal probe) has been placed in the vagina roughly 1 cm away from the cervix to evaluate the volume of the ovary and antral follicle counts (AFC). Investigations: General (CBC, urinalysis, Random blood sugar) when needed. Specific: Hormonal profile in all patients of the study, the following were obtained prior to the procedure: Anti-Mullerian hormone (AMH). FSH, Estradiol. - PRP preparation and time of injection On the day of PRP infusion (within 10 days after completion of menstrual bleeding) we will take 20 cc of venous blood from each participant of group A to prepare PRP. The blood will be transferred to a tube containing sodium citrate and centrifuged at 800 RPM for 15 min and 2000 RPM for 5 min in two stages, respectively. Then, by discarding part of the plasma, PRP will be prepared with a final concentration of one million platelets per microliter. The PRP will be injected into the ovary under spinal anesthesia and a transvaginal ultrasound guide. - Patien assessment and Follow up. patients injected with PRP will be managed expectantly for 6 weeks to allow spontaneous pregnancy, at the beginning of second menstrual cycle AMH, FSH, AFC will be reassessed. - 3months after the PRP injection, all women considered poor responders (2groups)will undergo assisted reproductive therapy with antagonist protocol followed by a dose of 450 units of FSH (Gonal F, CinnaGen, Iran). Six days after gonadotropin therapy, vaginal ultrasound will be performed to measure follicle diameter. Once the follicular size is 12 mm, the GnRH antagonist (Cetrorelix, Merck-Serono, Germany) will begin, and gonadotropin continued. When at least two dominant follicles reach the diameter of 18 mm on ultrasound, ovulation will be stimulated using 10,000 units of HCG, and oocyte retrieval will be performed under general anesthesia 34 to 36 h after the HCG injection and the two groups will be compared in terms of the outcomes such as duration of stimulation dosage of gonadotrophine serum of estradiol level on the triggering day ,number and quality of oocytes and embryons and clinical pregnancy


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 56
Est. completion date September 30, 2024
Est. primary completion date March 30, 2024
Accepts healthy volunteers No
Gender Female
Age group 20 Years to 45 Years
Eligibility Inclusion Criteria: - Women under the age of 40. - have been infertile for more than a year - have had at least one previous unsuccessful (or cancelled) IVF cycle. - having one of the criteria of poor ovarian response including anti mullerian hormone (AMH) level <1.1 ng /ml ,the antral follicle count of two ovaries in vaginal ultrasound <7 . Exclusion Criteria: - pregnancy(ruled out and documented before PRP injection) . Hydrosalpinex,uterine malformations and abnormal uterine cavity. - Partner with severe male factor - Ongoing malignancy. - Chronic pelvic pain - A history of major lower abdomen surgeries that resulted in pelvic adhesions.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Intra ovarian by platelet rich plasma
On the day of PRP infusion (within 10 days after completion of menstrual bleeding) we will take 20 cc of venous blood from each participant of group A to prepare PRP. The blood will be transferred to a tube containing sodium citrate and centrifuged at 800 RPM for 15 min and 2000 RPM for 5 min in two stages, respectively. Then, by discarding part of the plasma, PRP will be prepared with a final concentration of one million platelets per microliter. The PRP will be injected into the ovary under spinal anesthesia and a transvaginal ultrasound guide.

Locations

Country Name City State
Egypt Beni-suef university Hospital Bani Suwayf Beni Suef

Sponsors (1)

Lead Sponsor Collaborator
Beni-Suef University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary number of retrieved oocytes number of oocytes obtained in ovum pick up 1 month of induction for ICSI trial
See also
  Status Clinical Trial Phase
Recruiting NCT05969574 - Is Decreased Ovarian Reserve Related to an Increased Number of Previous Early Miscarriages?
Completed NCT04778358 - Higher Dose of Rekovelle in Oocyte Donors Phase 2
Completed NCT04052464 - The Study of the Implantation Window From Endometrial Biopsy With Gene Expression Methods
Completed NCT04108039 - Micronized Progesterone vs Gonadotropin-releasing Hormone (GnRH) Antagonist in Freeze-all IVF Cycles. N/A
Suspended NCT04669652 - Evaluating Piezo-ICSI. - The EPI Study. N/A
Completed NCT04524026 - RIOTC: Reducing the Impact of Ovarian Stimulation. Novel Approaches to Luteal Support in IVF-Study 2 Phase 2
Recruiting NCT05981898 - Opt-IVF Multi-center Trial 2 Including All Protocols N/A
Recruiting NCT05737381 - Quality of Human Embryos in IVF, Culturing in Differentiated Oxygen N/A
Recruiting NCT04447872 - The LUTEAL Trial: Luteal Stimulation vs. Estrogen Priming Protocol N/A
Completed NCT04425317 - Detection of SARS-CoV-2 in Follicular Fluid and Cumulus-oocyte-complexes in COVID-19 Patients N/A
Not yet recruiting NCT05932082 - The Impact of Myomectomy on IVF Outcomes N/A
Not yet recruiting NCT04283435 - Endometrial Effects of Sildenafil in Frozen-Thawed Cycles in Women With Thin Endometrium Phase 1
Recruiting NCT04654741 - The Rate of Embryo Euploidy in Progestin-primed Ovarian Stimulation Cycles Phase 4
Completed NCT04099784 - Health of Frozen Transferred Versus Fresh Transferred Children
Recruiting NCT05788822 - MVA to Improve the Pregnancy Outcome in Aged Infertility Women With Assisted Reproductive Technology N/A
Completed NCT04956848 - Comparing KIDScoreā„¢ D5 and iDAScore®. The KiDA Study N/A
Not yet recruiting NCT05954962 - Efficacy of Micronized Natural Progesterone vs GnRH Antagonist in the Prevention of LH Peak During Ovarian Stimulation. Phase 4
Not yet recruiting NCT02698488 - Embryo Selection by Metabolomic Profiling of Embryo Culture Medium With Mass Spectroscopy as an Adjunct to Morphology N/A
Completed NCT01385618 - Gene-polymorphisms Relating to Human Subfertility N/A
Recruiting NCT05893238 - Human Follicular Fluid Markers and Reproductive Outcomes in IVF